Undifferentiated pleomorphic sarcoma
MONDO:0002142An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate. It is also known as malignant fibrous histiocytoma.
Also known as: MFH, Storiform-pleomorphic MFH, Storiform-pleomorphic fibrous histiocytoma, Storiform-pleomorphic malignant fibrous histiocytoma, UPS, Unclassified Pleomorphic sarcoma (formerly "MFH"), Unclassified Pleomorphic sarcoma (formerly "malignant fibrous histiocytoma"), adult malignant fibrous histiocytoma
2866 clinical trials for this condition and its sub-types, 48 tagged with Undifferentiated pleomorphic sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Undifferentiated pleomorphic sarcoma
-
Can Pre-Surgery chemo boost outcomes in High-Risk Soft-Tissue sarcoma?
Disease control Not yet recruitingThis phase 3 trial compares adding doxorubicin and ifosfamide (AIM chemotherapy) before standard treatment with pembrolizumab, radiation therapy, and surgery versus standard treatment alone in patients with high-risk soft-tissue sarcomas that can be removed by surgery. Participan…
Phase 3 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug boost chemotherapy against rare sarcomas?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called DT-7012 to standard chemotherapy (doxorubicin) helps people with advanced soft tissue sarcoma, specifically two subtypes: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Participants receive either…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Triple attack on aggressive sarcoma: can radiation, immunotherapy, and chemo shrink tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial tests a three-part treatment for people with high-risk undifferentiated pleomorphic sarcoma (UPS), a rare cancer of soft tissue. Participants receive focused radiation (SBRT), the immunotherapy drug toripalimab, and a lower dose of the chemotherapy drug liposom…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemo alone in people with advanced soft tissue sarcoma. About 92 adults who have already had 1-2 prior chemotherapies will be…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental drug combo takes on rare sarcomas
Disease control Not yet recruitingThis early-phase trial tests a new drug called BOLD-100 combined with standard chemotherapy (doxorubicin) in 32 people with advanced soft tissue sarcomas that cannot be removed by surgery or have spread. The goal is to find the safest dose and see if the combination can shrink tu…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC